Tom Charlesworth, Director of Marketing Strategy and Corporate Development at biomodal examines how 6-base sequencing can unlock advancements in precision medicine.  Call it precision medicine, Genomics 3.0, or the age of multi-omics. However you choose to describe it, the underlying meaning is the same: Our ability to collect and analyse molecular data is improving, moving […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!